Darunavir Ethanolate CAS 635728-49-3 Purity ≥99.0% API Factory Anti-HIV HIV Protease Inhibitor
Ubonelelo loMvelisi kwiiMveliso eziNxulumene neDarunavir:
Darunavir CAS 206361-99-1
I-Darunavir Ethanolate CAS 635728-49-3
(2S,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98737-29-2
(2R,3S)-1,2-Epoxy-3-(Boc-Amino)-4-Phenylbutane CAS 98760-08-8
(3S)-3-(tert-Butoxycarbonyl)amino-1-Chloro-4-Phenyl-2-Butanone CAS 102123-74-0
| Igama leMchiza | Darunavir Ethanolate |
| Izithethantonye | DRV;Prezista;TMC114 Ethanolate;UNII-33O78XF0BW;N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]carbamic acid (3R,3aS,6aR)-hexahydrofuro [2,3-b]furan-3-yl ester compd.kunye ne-ethanol |
| Inombolo yeCAS | 635728-49-3 |
| Inombolo yeCAT | RF-API69 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C29H43N3O8S |
| Ubunzima beMolekyuli | 593.73 |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Umgubo weCrystalline oMhlophe okanye oMhlophe |
| Ukuchongwa kwe-IR | Ingqinelana ne-Spectrum esemgangathweni |
| Ukujikeleziswa okuthe ngqo | -0.5 ° ~ +0.5 ° |
| Izinto ezinxulumeneyo | (nge-HPLC) |
| Ukungahlambuluki Okukodwa okuphezulu | ≤0.20% |
| Ukungcola ngokupheleleyo | ≤0.50% |
| Amanzi (KF) | ≤1.0% |
| Intsalela kwi-Ignition | ≤0.10% |
| Iintsimbi ezinzima | ≤10ppm |
| Umxholo we-Ethanol | ≤7.5% (GC) |
| Izinyibilikisi ezishiyekileyo | IMethanol ≤0.30% |
| Ubunyulu | ≥99.0% (HPLC) |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | Darunavir Ethanolate HIV-1 Protease Inhibitor Anti-HIV Antiviral |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, Igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Darunavir Ethanolate (Prezista) sisithinteli se-HIV protease inhibitor.I-Derivative ye-Darunavir, isizukulwana sesibini i-HIV-1-protease inhibitor;ngokwesakhiwo iyafana ne-amprenavir.I-Antiviral.Yimveliso yophando enxulumene ne-COVID19.Ngelishwa, i-DRV inonyibiliko oluphantsi emanzini kunye nokungafumaneki kakuhle kwe-bioavailability, ngoko ke ifuna ulawulo olukwidosi ephezulu kakhulu ukuze ibonise ukusebenza konyango.I-Darunavir sisithinteli esinamandla esibanzi esisebenzayo ngokuchasene ne-HIV-1 yodwa ekliniki ene-cytotoxicity encinci.I-Darunavir yenza iibhondi ze-hydrogen kunye nee-athom zekhonkco ezingundoqo ezigciniweyo ze-Asp29 kunye ne-Asp30 yeprotease.Olu nxibelelwano lucetywa ukuba lubaluleke kakhulu kumandla ale khompawundi ngokuchasene ne-HIV yodwa ekwaziyo ukumelana ne-multiple protease inhibitors.Kuphononongo lwe-in vitro kwiiseli ze-MT-2, amandla e-darunavir makhulu kunalawo e-saquinavir, amprenavir, nelfinavir, indinavir, lopinavir kunye ne-ritonavir.I-Darunavir i-metabolized yi-hepatic cytochrome P450 (CYP) enzymes, ngokukodwa i-CYP3A.Idosi 'yokunyusa' ye-ritonavir isebenza njengesithinteli se-CYP3A, ngokwenjenjalo inyusa ukufumaneka kwe-darunavir bioavailability.I-Darunavir yayiyilwe ukwenza intsebenziswano eyomeleleyo kunye ne-enzyme ye-protease evela kwiintlobo ezininzi ze-HIV, kubandakanywa ubunzima obusuka kwizigulane ezinamava onyango ezine-mutati yokuxhathisa okuphindaphindiweyo.
